보건복지부, 1500억 규모 '임상 3상 특화펀드' 운용사 모집

This initiative addresses the 'Death Valley' of drug development by specifically targeting the capital-intensive and high-risk Clinical Phase 3 stage. It reflects a strategic governmental intervention to bolster the global competitiveness of the Korean Biopharma sector amid a tightening private investment environment.